Qiagen Stock - analyst consensus and earnings calendar in focus

Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 01:25 UTC. Details in the imprint.

Qiagen (NL0012169213) is drawing attention among diagnostics investors mainly through its analyst consensus and earnings timetable rather than fresh ad-hoc headlines. The next scheduled results and guidance updates will frame expectations for the molecular testing specialist.

What recent updates show

Qiagen’s most recent detailed corporate communication remains its earlier quarterly reporting and guidance commentary, which continues to frame investor expectations in the absence of new ad-hoc announcements.

The company’s investor-relations site lists financial reports, presentations and an earnings calendar, but no new market-moving releases have been posted in the latest daily cycle.

Weekly outlook and earnings calendar

With no fresh headlines, the focus shifts to the weekly outlook and the timing of Qiagen’s next results. The earnings calendar on the company’s website guides expectations for upcoming quarterly numbers and any possible guidance adjustments.

Investors typically watch for updates on core metrics such as adjusted earnings per share, revenue growth in sample technologies and diagnostic solutions, and free cash flow, plus any commentary on demand trends in clinical and research testing.

How analysts view the stock

Consensus data compiled by financial portals shows a mix of Buy, Hold and occasional Sell recommendations on Qiagen shares, with target prices often clustered around the current trading range.

These consensus numbers offer a reference point but should be seen as snapshots: ratings and price targets are routinely updated after each earnings release or guidance change, reflecting new information on margins, volumes and capital allocation.

What the company sells

Qiagen generates most of its revenue from molecular diagnostics and life science research tools, including sample preparation kits and assay technologies such as the QIAstat-Dx syndromic testing platform and the QIAsymphony automation system used in clinical laboratories worldwide.

Where the stock trades today

Qiagen stock (NL0012169213) trades on Xetra in euros; the most recently available Xetra closing price was EUR 32.14 on 06/19/2026 at 17:35 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.